Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications

9Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Chemotherapy is widely used to treat patients with cancer. However, resistance to chemotherapeutic drugs remains a major clinical concern. The mechanisms of cancer drug resistance are extremely complex and involve such factors such as genomic instability, DNA repair, and chromothripsis. A recently emerging area of interest is extrachromosomal circular DNA (eccDNA), which forms owing to genomic instability and chromothripsis. eccDNA exists widely in physiologically healthy individuals but also arises during tumorigenesis and/or treatment as a drug resistance mechanism. In this review, we summarize the recent progress in research regarding the role of eccDNA in the development of cancer drug resistance as well as the mechanisms thereof. Furthermore, we discuss the clinical applications of eccDNA and propose some novel strategies for characterizing drug-resistant biomarkers and developing potential targeted cancer therapies.

Cite

CITATION STYLE

APA

Luo, J., Li, Y., Zhang, T., Xv, T., Chen, C., Li, M., … Wan, S. (2023, January 30). Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2022.1092705

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free